NAD+

Clinical Disclaimer: The information in this monograph is for qualified healthcare professionals. Injectable NAD+ is not FDA-approved for any therapeutic indication. Use in clinical practice is investigational. Oral NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) are distinct products regulated as dietary supplements.

1. Introduction and Overview

Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine dinucleotide coenzyme required for life. It functions as a hydride acceptor in oxidation–reduction reactions — the "plus" in NAD+ denotes the oxidized form — and as a substrate consumed by three families of enzymes that regulate metabolism, DNA repair, and cell signaling. Every mammalian cell maintains an intracellular NAD+ pool on the order of 0.2–0.5 mM, partitioned between cytoplasmic, mitochondrial, and nuclear compartments, and this pool is continuously turned over by biosynthesis and consumption at rates that track metabolic demand.

NAD+ is increasingly the focus of translational aging and metabolic research because intracellular NAD+ levels decline with age across multiple tissues, and that decline is mechanistically linked to mitochondrial dysfunction, impaired DNA repair, altered stem-cell function, and metabolic disease. Restoring tissue NAD+ levels has therefore become a therapeutic goal, pursued through three main strategies: direct parenteral NAD+ administration, oral NAD+ precursors (nicotinamide riboside [NR], nicotinamide mononucleotide [NMN]), and inhibition of NAD+-consuming enzymes such as CD38.

This monograph focuses on injectable (parenteral) NAD+ as used in clinical and wellness practice. Oral precursors are discussed only for context — they are a distinct regulatory and therapeutic category with a far larger randomized-controlled-trial evidence base than injectable NAD+ itself.

2. Chemistry and Biochemistry

2.1 Structure and basic properties

NAD+ is a dinucleotide composed of nicotinamide linked to an adenine base via two ribose-phosphate units. Its molecular formula is C21H27N7O14P2 (free acid, MW 663.43 g/mol). Reconstituted parenteral preparations are typically the disodium salt (MW 685.41 g/mol) at physiologic pH. NAD+ exists in equilibrium with its reduced form NADH and with phosphorylated forms NADP+/NADPH, and the cellular ratio of these redox couples is one of the most tightly regulated parameters in metabolism.

2.2 Biosynthesis and salvage

Mammalian cells synthesize NAD+ through three pathways:

• De novo pathway from tryptophan via the kynurenine route — relatively slow and minor contributor in most tissues.
• Preiss–Handler pathway from dietary nicotinic acid (niacin) — efficient in liver and gut.
• Salvage pathway from nicotinamide (NAM) and nicotinamide riboside (NR), via nicotinamide phosphoribosyltransferase (NAMPT) and nicotinamide mononucleotide adenylyltransferases (NMNATs) — the dominant route in most tissues.

Most intracellular NAD+ is recycled through the salvage pathway rather than synthesized from dietary precursors. NAMPT is the rate-limiting enzyme and is itself regulated by circadian rhythms, nutrient status, and inflammation.

2.3 NAD+-consuming enzyme families

3. Age-Related NAD+ Decline

Intracellular NAD+ concentrations fall progressively with age across many tissues — skeletal muscle, brain, skin, and immune cells have each been shown to exhibit age-associated NAD+ decline in published human studies. The decline is driven primarily by two factors: (1) increased expression and activity of CD38 with age and chronic inflammation, which accelerates NAD+ consumption, and (2) chronic low-grade activation of PARPs in response to accumulated DNA damage.

Consequences of low tissue NAD+ include reduced sirtuin activity (particularly SIRT1 and SIRT3), impaired mitochondrial function, increased mitochondrial reactive oxygen species production, altered lipid handling, and impaired DNA repair. In aging model organisms and in aged mice, restoring NAD+ through precursor supplementation or CD38 inhibition has been shown to reverse many of these downstream phenotypes. Whether this translates into clinically meaningful benefit in humans is the central question of the ongoing NAD+ boosting research program.

4. Mechanism of Action

NAD+ replenishment acts through restoration of normal cellular NAD+-dependent signaling. The three primary downstream axes are:

4.1 Sirtuin-mediated effects

Sirtuins are NAD+-dependent enzymes that remove acyl groups from target proteins in a reaction that consumes one molecule of NAD+ per deacylation. Restoring NAD+ increases sirtuin activity, with downstream effects including enhanced mitochondrial biogenesis (via PGC-1alpha deacetylation), improved mitochondrial oxidative phosphorylation, altered lipid and glucose metabolism, and — in model organisms — extended stress tolerance.

4.2 PARP-mediated DNA repair

PARPs consume NAD+ to poly-ADP-ribosylate substrate proteins at sites of DNA damage. Chronic DNA damage in aging cells drives continuous PARP activation, which can deplete local NAD+ pools. Adequate NAD+ supply supports normal DNA repair capacity; conversely, NAD+ deficiency impairs repair and contributes to genomic instability.

4.3 CD38 and NAD+ homeostasis

CD38 is a cell-surface ectoenzyme that hydrolyzes extracellular NAD+ and is a major contributor to the age-associated decline in tissue NAD+ levels. CD38 expression rises with chronic inflammation ("inflammaging") and with senescent-cell accumulation. Exogenous NAD+ administration transiently raises extracellular NAD+ levels but is also a substrate for CD38, which is why rate-limited infusion strategies and co-administration with CD38 inhibitors are active areas of investigation.

5. Clinical Evidence

5.1 Injectable NAD+ — human data

Published human data on parenteral NAD+ itself is limited. Grant et al. (Front Aging Neurosci 2019) conducted a pilot study of 6-hour IV NAD+ infusions in 8 participants, characterizing plasma and urine NAD+ metabolome changes. Small case series and observational reports have described subjective effects on energy, cognition, and fatigue during multi-day infusion protocols. No large randomized placebo-controlled trials of injectable NAD+ have been completed or published as of early 2026.

5.2 Oral NAD+ precursors — human data

In contrast, oral NAD+ precursors have a substantial randomized-controlled-trial literature:

• Martens et al. (Nat Commun 2018) — 8-week randomized trial of 1 g/day NR in middle-aged and older adults (n=24); demonstrated well-tolerated elevation of blood NAD+ and reduced systolic blood pressure.
• Yoshino et al. (Science 2021) — 10-week trial of 250 mg NMN in prediabetic postmenopausal women (n=25); improved muscle insulin sensitivity without changes in body composition.
• Elhassan et al. (Cell Rep 2019) — 21-day trial of NR in aged men (n=12); increased skeletal muscle NAD+ metabolome and favorable transcriptomic signatures.
• Conze et al. (Sci Rep 2019) — long-term safety of 500 mg NR twice daily in overweight adults; well tolerated over 8 weeks.

Collectively these trials establish that oral NAD+ precursors elevate blood and tissue NAD+ and are well tolerated. Whether IV NAD+ offers additive or distinct benefits beyond oral precursor supplementation has not been rigorously tested.

6. Prescribing Considerations

6.1 Routes of administration

6.2 Typical protocols

No FDA-established dosing exists for any injectable NAD+ formulation. Common compounded-practice protocols include an initial loading course of 5–10 near-daily IV infusions of 250–500 mg, followed by maintenance dosing every 4–12 weeks. Some practices use higher loading doses (up to 1000 mg per session) delivered over 4–8 hours. Titration should be guided by patient tolerance — infusion-rate-dependent flushing, tachycardia, and chest tightness are common and dose-limiting.

6.3 Practical pearls

• Slow the infusion rate whenever symptoms develop — most infusion-related effects are rate-dependent rather than dose-dependent.
• Hydrate patients before and during infusions; many practices add magnesium and B-complex vitamins to the same line for perceived tolerability benefit.
• Consider methylation support (methylated B12, folate, possibly SAMe) in patients receiving repeated courses, given methyl-group demand during NAD+ metabolism and the risk of rising homocysteine.
• Counsel patients that subjective benefits during infusion (energy, clarity) do not equate to proven sustained efficacy — trial evidence for injectable NAD+ remains limited.
• Oral NR or NMN may provide a more convenient and evidence-supported NAD+ boost between IV courses for patients seeking durable elevation.

7. Safety and Monitoring

7.1 Common adverse effects

Infusion-related reactions are the dominant safety consideration. The classic combination of flushing, chest tightness, tachycardia, nausea, and anxiety occurs with rapid IV administration and is almost always avoided by slowing the infusion. Post-infusion fatigue or headache is described by a minority of patients.

7.2 Serious adverse events

No serious adverse events definitively attributable to parenteral NAD+ have been reported in published clinical experience. Rate-related hemodynamic effects are avoidable with appropriate titration. Theoretical concerns about supporting occult malignancy growth — based on tumor metabolic dependence on NAD+ — have not been substantiated clinically but warrant age-appropriate cancer screening before repeated courses.

7.3 Monitoring

• CBC, CMP (including LFTs and renal function), lipid panel, HbA1c at baseline and every 3–6 months on repeated courses.
• Homocysteine at baseline and every 6 months on long-term therapy — NAD+ metabolism consumes methyl groups.
• Vital signs and patient symptom reporting at every infusion.
• Age-appropriate cancer screening current before initiating any repeated-course protocol.

8. Regulatory Status and Sourcing

Injectable NAD+ is not FDA-approved for any therapeutic indication. Compounded parenteral NAD+ is prepared by 503A and 503B pharmacies under variable standards; identity, purity (ideally by HPLC), and endotoxin testing should be verifiable on the Certificate of Analysis for every lot dispensed. NAD+ is listed on the WADA prohibited list only in specific formulations — prescribers of competing athletes should verify current WADA status before use.

Oral NAD+ precursors — nicotinamide riboside (brand names NIAGEN and others) and nicotinamide mononucleotide — are marketed as dietary supplements under DSHEA in the United States. They have GRAS notifications and safety profiles established by multiple human trials. NMN specifically has been the subject of evolving FDA regulatory positioning; prescribers should verify current status when recommending specific products.

9. Summary and Outlook

NAD+ is a central redox and signaling coenzyme whose age-associated decline is mechanistically linked to multiple age-related pathologies. The translational case for restoring NAD+ through precursor supplementation or injectable administration is strong in preclinical models but incompletely validated in humans — the evidence for oral precursors (NR, NMN) substantially exceeds the evidence for parenteral NAD+ itself. For prescribers, this means framing IV NAD+ protocols honestly as investigational, selecting patients with realistic expectations, using appropriate infusion rates, and documenting the informed-consent conversation. For clinical research, the field awaits adequately powered randomized controlled trials of injectable NAD+ that would establish whether it confers benefits beyond those of oral precursors.

Bottom line: NAD+ biology is real, oral precursor data is substantial, parenteral NAD+ data is limited. Prescribe accordingly, set expectations accordingly, and document informed consent.